This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Live Chat

BOSTON ( TheStreet) -- Welcome to the first ever Biotech Stock Mailbag Live Chat. The floor is yours.

I'm here for the next hour or so to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing in the box below.

The American Society of Clinical Oncology (ASCO) meeting kicks off in a few weeks, so we can talk about hot cancer stocks like Exelixis (EXEL), YM Biosciences (YMI) or Dendreon (DNDN).

If you're a fan of large-cap biotech stocks, we can talk about how the emergence of oral multiple sclerosis drugs is affecting Biogen Idec (BIIB). Celgene (CELG - Get Report) is dealing with controversy over secondary cancer risks tied to its most important drug Revlimid, so let's hash out the issue. How about discussing Amgen (AMGN) and the pros and cons of offering its first shareholder dividend?

I never shy away from controversial topics, so let's argue about the prospects for Spectrum Pharmaceuticals (SPPI - Get Report), Cell Therapeutics (CTIC), Delcath Systems (DCTH), Cytori Therapeutics (CYTX) or Radient Pharmaceuticals (RPC).

New drug launches are a big investment theme in 2011, so bring your questions and comments regarding Human Genome Sciences (HGSI), Somaxon Pharmaceuticals (SOMX), Avanir Pharmaceuticals (AVNR) or InterMune (ITMN).

It's your Biotech Stock Mailbag Live Chat, so let's get started.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
AVNR $16.96 0.00%
DNDN $0.06 -6.02%
CELG $131.25 0.00%
EXEL $5.73 0.00%
SPPI $6.92 0.00%


Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs